MWC link to promising COVID-19 treatment
24 April 2020
Professor Peter Tyler, MWC Associate Investigator at the Ferrier Research Institute, Victoria University of Wellington, created the antiviral drug Galidesivir which is in the front-running for potential use in the treatment of COVID-19.
Galidesivir is now undergoing clinical trials for the treatment of patients with COVID-19 in Brazil. The antiviral drug was originally designed and synthesised by Professor Tyler as part of an intellectual property licence partnership agreement with BioCryst Pharmaceuticals in the US.
See the full article on the Radio New Zealand website.